The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 16, 2021
Filed:
Aug. 23, 2018
Applicant:
Pfizer Inc., New York, NY (US);
Inventor:
Joseph John Binder, San Diego, CA (US);
Assignee:
Pfizer Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 31/436 (2006.01); A61K 31/44 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/404 (2006.01); A61K 31/7088 (2006.01); A61K 39/395 (2006.01); C12N 7/00 (2006.01); C12N 9/64 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001193 (2018.08); A61K 31/404 (2013.01); A61K 31/436 (2013.01); A61K 31/44 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/7088 (2013.01); A61K 39/00 (2013.01); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/705 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); C12N 7/00 (2013.01); C12N 9/6424 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/645 (2013.01); A61K 2039/70 (2013.01); C07K 2317/75 (2013.01); C07K 2319/40 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10371 (2013.01); C12N 2830/006 (2013.01); C12N 2840/20 (2013.01); C12N 2840/203 (2013.01); C12Y 304/21077 (2013.01);
Abstract
The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.